A61K 2039/52
Bacterial cells
Official title: {Bacterial cells; Fungal cells; Protozoal cells}
A61K2039/52 (Bacterial cells) appears on 1,901 US grants and 2,642 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,901
- Published applications
- 2,642
- Assignees
- 1,169
- Inventors
- 4,116
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 5 | 0 |
| 1978 | 3 | 0 |
| 1979 | 0 | 0 |
| 1980 | 2 | 0 |
| 1981 | 3 | 0 |
| 1982 | 7 | 0 |
| 1983 | 3 | 0 |
| 1984 | 2 | 0 |
| 1985 | 1 | 0 |
| 1986 | 1 | 0 |
| 1987 | 1 | 0 |
| 1988 | 3 | 0 |
| 1989 | 7 | 0 |
| 1990 | 3 | 0 |
| 1991 | 4 | 0 |
| 1992 | 2 | 0 |
| 1993 | 2 | 0 |
| 1994 | 7 | 0 |
| 1995 | 10 | 0 |
| 1996 | 7 | 0 |
| 1997 | 13 | 0 |
| 1998 | 19 | 0 |
| 1999 | 25 | 0 |
| 2000 | 30 | 0 |
| 2001 | 27 | 6 |
| 2002 | 28 | 51 |
| 2003 | 29 | 84 |
| 2004 | 23 | 92 |
| 2005 | 39 | 106 |
| 2006 | 50 | 94 |
| 2007 | 38 | 89 |
| 2008 | 49 | 97 |
| 2009 | 51 | 120 |
| 2010 | 78 | 122 |
| 2011 | 71 | 114 |
| 2012 | 74 | 112 |
| 2013 | 73 | 115 |
| 2014 | 92 | 112 |
| 2015 | 91 | 127 |
| 2016 | 113 | 139 |
| 2017 | 99 | 135 |
| 2018 | 116 | 122 |
| 2019 | 104 | 126 |
| 2020 | 115 | 124 |
| 2021 | 93 | 114 |
| 2022 | 74 | 99 |
| 2023 | 65 | 107 |
| 2024 | 58 | 113 |
| 2025 | 48 | 76 |
| 2026 | 41 | 46 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Use of E. coli strains expressing high level of α-Gal to modulate immunity and provide protection against infectious diseases in animals29 Sep 2026US 12,745,790 B2Biologicke Centrum AV CR v. v. i.
- Compositions and methods for preventing and treating virus infection15 Sep 2026US 12,734,234 B2University of Virginia Patent Foundation
- Tumor immunotherapy composition based on antigen-presenting cells activated by attenuated listeria monocytogenes, preparation method therefor and application thereof11 Aug 2026US 12,702,681 B2Shanghai RoyalTech Med CO., Ltd
- Edible vaccination against microbial pathogens4 Aug 2026US 12,697,378 B2Dalan Animal Health, Inc.
- Live attenuated strain of Streptococcus pneumoniae and pharmaceutical compositions comprising a live attenuated strain of S. pneumoniae4 Aug 2026US 12,698,471 B2UCL Business PLC
- Orally-delivered vaccines for domesticated and wild animals to prevent pathogen spread using recombinant probiotic bacteria1 Oct 2026US 2026/0295027 A1
- Live attenuated leishmania parasite vaccines with enhanced safety characteristics17 Sep 2026US 2026/0273036 A1Ohio State Innovation Foundation
- Uses of bifidobacterium longum transitional microorganism10 Sep 2026US 2026/0263538 A1Societe des Produits Nestle S. A.
- Materials and Methods For Cell-Free Expression of Vaccine Epitope Concatemers27 Aug 2026US 2026/0250332 A1Leidos, Inc.
- Oral vaccine20 Aug 2026US 2026/0240985 A1WestfäLische Wilhelms-UniversitäT MüNster
Most cited
By later US patents
- Immunizing compositions comprising nucleic acids encoding the HIV-1 matrix protein myristate binding site1,449US 7,718,180 B22010
- Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant395US 6,406,705 B1Coley Pharmaceutical GmbH · 2002
- Recombinant new castle disease virus RNA expression systems and vaccines164US 6,146,642 AMount Sinai School of Medicine of the City University of New York · 2000
- System and method for measuring animals128US 8,036,429 B22011
- Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response111US 5,830,702 AThe Trustees of the University of Pennsylvania · 1998